4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Non-Small Cell Lung Cancer Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Non-Small Cell Lung Cancer by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 2335 ongoing clinical trials involving Non-Small Cell Lung Cancer
Of the 2335 trials,895 trials are in Phase II
Furthermore, 533 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Non-Small Cell Lung Cancer by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Non-Small Cell Lung Cancer, an Oncology condition. The largest number of ongoing clinical trials for Non-Small Cell Lung Cancer is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Non-Small Cell Lung Cancer-related drug trials.

AstraZeneca Plc: The leading ongoing Non-Small Cell Lung Cancer related clinical trial sponsor

AstraZeneca Plc is the top sponsor for Non-Small Cell Lung Cancer-related ongoing clinical trials.

Sun Yat-sen University, National Cancer Institute US, F. Hoffmann-La Roche Ltd and Pfizer Inc are among other notable clinical trial sponsors involved in Non-Small Cell Lung Cancer. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Non-Small Cell Lung Cancer

Pembrolizumab (Keytruda), Nivolumab (Opdivo, Opdyta) and Bevacizumab (Avastin) are among the key marketed drugs involving Non-Small Cell Lung Cancer.

Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist mechanism of action. Pembrolizumab is formulated as lyophilised powder for solution, solution concentrate for intravenous route of administration. Pembrolizumab was first approved in 2014 and is marketed globally in the US, UK, China, Japan, Germany, and France by several prominent pharma giants including Merck Sharp & Dohme Corp.

Nivolumab (Opdivo, Opdyta) is a human IgG4 anti-PD-1 monoclonal antibody. It functions via Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist mechanism of action. Nivolumab is formulated as solution and concentrate solution for intravenous route of administration. Nivolumab was first approved in 2014 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Bristol-Myers Squibb Co.

Explore the latest trends and actionable insights on the Non-Small Cell Lung Cancer Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Non-Small Cell Lung Cancer Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store